SS
AKTX

SBI Securities’s Akari Therapeutics AKTX Stock Holding History

SBI Securities’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143 Buy
14
+9
+180% +$78 ﹤0.01% 3419
2026
Q1 		$26 Hold
5
– – ﹤0.01% 3706
2025
Q4 		$58 Buy
+5
New +$116 ﹤0.01% 3545
2025
Q1 		– Hold
0
– -$6 – 4127
2024
Q4 		– Hold
0
– – – 3969

Other funds holding AKTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

SBI Securities's AKTX Position: Q2 2026 in Review

SBI Securities increased its Akari Therapeutics (AKTX) stake by 180% in Q2 2026, buying an estimated $78 and bringing the position to 14 shares worth $143. The position accounts for ﹤0.01% of the portfolio, ranked #3419.

SBI Securities first reported a position in AKTX in Q4 2025 and has held it in 3 quarters since. 3 funds tracked by Wall St. Rank hold AKTX as of Q2 2026.

  • SBI Securities held 14 shares of Akari Therapeutics worth $143 as of Q2 2026.
  • SBI Securities bought 9 Akari Therapeutics shares in Q2 2026, an estimated $78.
  • Akari Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3419 holding.
  • SBI Securities first reported a position in Akari Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 3 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.